Startup profile · funding coverage
CAMP4 Therapeutics
Regulatory RNA-targeting therapeutics to upregulate gene expression.
Stage
public
Status
public
Coverage
full
Why CAMP4 Therapeutics is interesting
CAMP4 maps regRNA biology to restore healthy protein levels — a16z led the Series A before the company went public on Nasdaq (CAMP).
Key facts
- Public (Nasdaq: CAMP): private placement and public listing activity in 2025 (CAMP4 IR)
- Series A (2018): $30M led by a16z; Polaris, Kraft Group participated (GenomeWeb)
- Series B (2022): $100M led by Enavate Sciences; a16z re-upped (BusinessWire)
- Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24
- Source: https://www.genomeweb.com/business-news/computational-biology-startup-camp4-therapeutics-launches-30m-series-funding
Investors in our directory
Funds linked from CAMP4 Therapeutics's profile — open a fund page for stage focus and related deal articles.
Related funding articles
Venture Capital Tracker pieces that cover CAMP4 Therapeutics's financing or category context.
Last updated: 2026-07-24